Open AccessInhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists
Author(s) -
Yvonne D. Krom,
Nuno Pires,
J. Wouter Jukema,
Margreet R. de Vries,
Rune R. Frants,
L.M. Havekes,
K VANDIJK,
Paul H.A. Quax
Publication year - 2006
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1016/j.cardiores.2006.10.024
Subject(s) - neointima , restenosis , estrogen receptor , agonist , receptor , pharmacology , chemistry , medicine , stent , breast cancer , cancer
Neointima formation is the underlying mechanism of (in-stent) restenosis. 17beta-Estradiol (E2) is known to inhibit injury-induced neointima formation and post-angioplasty restenosis. Estrogen receptor alpha (ERalpha) has been demonstrated to mediate E2 anti-restenotic properties. However, the role of estrogen receptor beta (ERbeta) is not fully elucidated. In the present study, the specific role of vascular ERalpha and ERbeta in neointima formation is assessed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom